Brian Piekos - Sep 9, 2024 Form 4 Insider Report for KalVista Pharmaceuticals, Inc. (KALV)

Role
Chief Financial Officer
Signature
/s/ Benjamin L. Palleiko, Attorney-in-Fact
Stock symbol
KALV
Transactions as of
Sep 9, 2024
Transactions value $
$0
Form type
4
Date filed
9/11/2024, 04:34 PM
Previous filing
Feb 5, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KALV Employee Stock Option (right to buy) Award $0 +100K $0.00 100K Sep 9, 2024 Common Stock 100K $11.87 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests over a 4 year period: 25% on September 9, 2025, after which 1/48th of the total shares vest monthly, subject to continued service through each vesting date.